HC Wainwright & Co. Maintains Buy on Reviva Pharmaceuticals, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Reviva Pharmaceuticals and raises the price target from $10 to $20.
October 31, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals' price target has been raised from $10 to $20 by HC Wainwright & Co.
The news of a price target increase is typically seen as a positive signal by the market, indicating that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100